checkAd

     156  0 Kommentare Menarini Ricerche Announces SEL24/MEN1703 Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial - Seite 3

    The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of €3.793 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, gastroenterology, pneumology, infectious diseases, diabetology, inflammation, and analgesia. With 17 production sites and 10 Research and Development centers, Menarini's products are available in 140 countries worldwide. For further information, please visit www.menarini.com

    Logo: https://mma.prnewswire.com/media/1345630/DIAMOND_1_Logo.jpg
    Logo: http://mma.prnewswire.com/media/520214/Menarini_Ricerche_Logo.jpg

    DIAMOND-01 Logo (PRNewsfoto/Menarini Ricerche)

    Seite 3 von 3




    PR Newswire (engl.)
    0 Follower
    Autor folgen
    Verfasst von PR Newswire (engl.)
    Menarini Ricerche Announces SEL24/MEN1703 Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial - Seite 3 - SEL24/MEN1703 is being Evaluated for the Treatment of Acute Myeloid Leukemia (AML) - Poster Accepted for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting POMEZIA, Italy and ROME, Dec. 1, 2020 /PRNewswire/ - Menarini …